Hair cloning is being developed by companies like Kangstem Biotech and Stemson, with potential availability in a few years. Initial costs are expected to be high, but prices may decrease over time.
The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. It also mentions a new hair transplant therapy approved by the government.
Peptides, specifically GHK-Cu, are being considered for hair growth benefits, such as increasing blood flow to the scalp and preventing hairfollicle shrinkage. A user reported starting GHK-Cu after hearing it made a friend's hair thicker.
A 28-year-old shared surprising hair regrowth progress after 20 days using topical minoxidil, micro needling, GHK-cu, and BPC-157 injections. The user noted a significant reduction in their bald spot and overall hair improvement.
A 21-year-old experiencing significant hair loss is considering a hair transplant and has been using finasteride and biotin, with plans to switch to dutasteride and oral minoxidil for better regrowth. They are seeking advice on the number of grafts needed, with suggestions ranging from 2,500 to 6,000, and are exploring different clinics and treatment options.
2% fucoidan alleviated AGA symptoms, promoted hair growth, and increased hair density in mice. Fucoidan is considered safe for humans as a supplement and topical skincare product, with potential therapeutic effects against AGA.
The conversation is about seeking updates on new hair loss treatments, specifically mentioning scube3 and GT20029, with one person mentioning HMI_115 as showing promising results.
Microneedling with needle lengths of 1.5mm to 2.5mm to stimulate hairfolliclestemcells for potential hair growth. Using needles longer than 2.5mm is not recommended due to risk of puncturing veins in the scalp. A dermastamp is suggested over a roller.
Scientists at UCLA have developed a promising treatment for male pattern baldness using a molecule called PP405, which can potentially stimulate dormant hair follicles. Initial trials showed significant results within a week, but larger clinical trials are needed to confirm its efficacy and safety.
Topical Metformin shows potential for regenerating hair follicles and minimizing scarring in hair transplant donor areas, similar to Verteporfin but without its side effects. The discussion suggests considering Metformin for post-hair transplant care, though more human trials are needed.
The conversation is about experimenting with microneedling and growth factor topicals for hair growth, avoiding Minoxidil due to shedding concerns. The treatment includes microneedling, growth factor topicals, finasteride, biotin, and a caffeine shampoo.
A user had a 2250 graft hair transplant using both FUT and FUE methods, and is currently using finasteride, minoxidil, multivitamins, and biotin. Opinions vary on the effectiveness and appearance of the procedure, with some suggesting additional treatments or considering alternative options like shaving or using a hair system.
A peptide from Japanese water chestnut fruit may help with hair loss by suppressing DHT's effect on hairfollicle cell death, potentially serving as a finasteride alternative. The treatment's effectiveness and safety in humans remain uncertain.
A 19-year-old with rapid hair loss since 16 is considering a hair transplant but refuses to take finasteride or any 5α-Reductase inhibitors. They are currently using minoxidil, tretinoin, and microneedling with a Derminator 2, and only want hair until age 27.
Verteporfin treatment shows promise for hair regeneration and reducing scar tissue in hair transplants. Some users plan to try verteporfin with hair transplants, and it may also be combined with PRP in future experiments.
The conversation discusses the potential of Verteporfin for hair regeneration and improving hair transplant surgery to leave no scars. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.
A user shared a 17-month update on their hair loss treatment, which included a hair transplant of 2300 grafts, using a topical solution of minoxidil and finasteride, a laser cap, and ketoconazole shampoo. They are considering another transplant and seeking honest feedback on their progress, while others share their own experiences and advice on hair loss treatments.
The conversation discusses hair loss treatments, mentioning minoxidil, finasteride, RU58841, VDPHL, GT20029, and follicle cloning as potential solutions. It also reveals that the discussion about PP405 was an April Fool's joke.
A user shared their positive experience with Trichogenics for hair restoration, highlighting their unique zigzag hairline technique and personalized attention. They had 1700 follicles transplanted and praised the natural results.
The conversation discusses the effectiveness of Regenera Activia stemcells versus Cellgenic exosomes for hair loss treatment. The user has been using topical minoxidil 5% and 0.001% estradiol for a year without results.
A 16-year-old started using topical finasteride, minoxidil, and dermapen for hair regrowth, along with natural DHT blockers. Advice given includes being patient and considering waiting until 18-21 to use finasteride.
GT20029 shows promising results for hair loss treatment, with potential approval in China by 2026 or 2027, but U.S. approval may take longer. It could serve as an alternative to finasteride, with a potentially better side effect profile.
The conversation discusses the importance of scalp skin barrier health in hairfollicle cycling, suggesting treatments like ceramides or niacinamide to support hair growth. It also mentions the use of finasteride for hair loss.
Hair loss involves more than just DHT, with genetic factors like TRPS affecting hair follicles. Treatments such as Amplifica's AMP-601 and AMP-303 target stemcells for potential hair growth solutions.
A user on finasteride, minoxidil, dermastamp, and Nizoral is seeing baby hairs and asks if it's regrowth. Another user confirms it is regrowth and encourages them to continue.
A user's father experienced hair regrowth and other health improvements after two IV exosome treatments. The user also had four rounds of exosome therapy, noting significant hair regrowth and relief from headaches, but no change in gray hair.
A 23-year-old male is experiencing diffuse hair loss and miniaturization, possibly due to high IGE levels after using tofacitinib. He seeks advice and has not yet consulted a dermatologist.
The conversation is about hair loss treatments, specifically the anticipation for the release of a new treatment, GT20029, by 2028. Users are discussing their experiences with current treatments like finasteride and dutasteride, and the potential of future treatments, including FAK inhibitors and verteporfin trials.